OK, the headline and press release basically have nothing to do with the underlying paper.
The paper itself is a small sample size (24) trial that looks at tolerance. There are no statistically significant physiological effects of dosing with NR in the paper. You see a small increase in the levels of various metabolites that you would expect to see increase after dosing. They only look at cardiovascular effects, and the results are inconclusive at best.
University press offices are doing nobody any favors with this kind of thing. It has to stop.
This was a Phase 1 study, which means that it was designed exclusively to test safety and tolerability of the agent. This explains both the small sample size and the crossover design. I wouldn't expect there to be even tentative assessment of effect until they run a larger Phase 2 trial. As for the press office, all it would know (or care) is that this was published in a decent journal.
The paper itself is a small sample size (24) trial that looks at tolerance. There are no statistically significant physiological effects of dosing with NR in the paper. You see a small increase in the levels of various metabolites that you would expect to see increase after dosing. They only look at cardiovascular effects, and the results are inconclusive at best.
University press offices are doing nobody any favors with this kind of thing. It has to stop.
https://www.nature.com/articles/s41467-018-03421-7.pdf